Highlight Therapeutics announces the appointment of Mercedes Diz as Chief Executive Officer, marking a new stage in the company’s strategic development.

Mercedes brings more than two decades of international experience in medical dermatology, strategic leadership, business development and global marketing. Prior to joining Highlight, she spent over twenty years at Almirall, a global pharmaceutical company focused on medical dermatology, where she served as Chief Marketing Officer and member of the Executive Committee. During her tenure, she played a key role in shaping the company’s international strategy, pipeline development and commercial growth. Earlier in her career, she held commercial and marketing roles at Pfizer, DuPont Pharma and Allergan.

Her appointment reinforces Highlight Therapeutic’s ambition to continue advancing innovative solutions in dermato-oncology, building on the company’s scientific foundation and ongoing clinical development programs.

“I am honoured to step into the role of CEO of Highlight Therapeutics, a company committed to addressing one of the fastest-growing and underserved medical challenges: skin cancer,” said Mercedes Diz. “Innovation only matters if it reaches patients. That is why we work closely with dermatologists, clinical researchers and partners to ensure that science translates into real clinical impact.”

With a strong background combining scientific training —holding a degree in Biochemistry and Molecular Biology— and executive education in Business Administration and Management, Mercedes brings a unique perspective at the intersection of science and strategy.

Her leadership marks a renewed commitment to strengthening Highlight Therapeutics’s position in dermato-oncology and continuing to translate scientific innovation into meaningful therapeutic alternatives for patients.